Stock GRTS GRITSTONE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Market Closed - Nasdaq
Other stock markets
 21:00:00 02/05/2024 BST 		5-day change 1st Jan Change
0.87 USD -0.42% Intraday chart for Gritstone bio, Inc. +13.80% -57.35%
04-30 Gritstone Bio, Inc. Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA Vaccine at ESCMID Global 2024 CI
04-29 Gritstone Bio, Inc. Announces Board Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
AQ
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
AQ
Gritstone Bio, Inc. Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA Vaccine at ESCMID Global 2024
CI
Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
AQ
Gritstone Bio, Inc. Announces Board Changes
CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
PR
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of 'Off-the-Shelf' Neoantigen Vaccine Platform
AQ
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
AQ
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform
CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
PR
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
AQ
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
PR
Top Midday Decliners
MT
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants
MT
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
AQ
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall
MT
Gritstone Bio Starts Public Offering; Shares Drop After-Hours
MT
Gritstone bio Announces Proposed Public Offering
AQ
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRTS Stock
  4. News Gritstone bio, Inc.